Introduction
Candidates preparing for healthcare IB interviews need a clear answer to a question that comes up in almost every process: "Why healthcare over other groups?" A generic answer about healthcare being "interesting" or "growing" will not differentiate you. You need to articulate the specific structural differences that make healthcare IB a fundamentally different experience from TMT, FIG, energy, or generalist coverage. This article gives you the framework.
The Three Core Differentiators
Regulatory Complexity Embedded in Every Transaction
Other coverage groups deal with regulation as an occasional factor. Healthcare bankers deal with it as a constant. In TMT, regulatory review might matter for a large platform acquisition (antitrust). In energy, environmental permitting affects project finance. But in healthcare, every transaction at every size involves regulatory considerations that directly affect valuation, structure, and timing.
A $500 million physician practice management acquisition requires analysis of corporate practice of medicine (CPOM) laws, Stark Law compliance, Anti-Kickback Statute implications, state licensure transfers, and potentially certificate of need approvals. A $15 billion pharma deal adds FDA transfer of marketing authorizations, patent assignment complications, and FTC review with healthcare-specific theories of competitive harm. No other coverage group faces this density of regulatory touchpoints on routine transactions.
Specialized Valuation Methods
Every coverage group has its valuation quirks, but healthcare is the only group where the core valuation methodology changes completely depending on the sub-sector. A healthcare banker needs to be fluent in at least four distinct frameworks:
| Sub-Sector | Primary Valuation | Why Standard DCF Falls Short |
|---|---|---|
| Pre-revenue biotech | rNPV | No revenue to project; binary clinical risk cannot be captured in a discount rate |
| Big Pharma | Sum-of-the-parts DCF | Patent expirations create known revenue cliffs; single-multiple approach masks product-level dynamics |
| Healthcare services | Adjusted EBITDA multiples | Adjustments (owner comp, pro forma add-ons, non-recurring items) can change EBITDA by 20-40% |
| Medical devices | Procedure volume build | Revenue = procedures x devices x ASP; each variable has distinct, non-financial drivers |
In TMT, you can value a software company, a semiconductor firm, and a media conglomerate using variations of the same DCF and EV/Revenue framework. In healthcare, the analytical toolkit for a pre-revenue biotech has almost nothing in common with the toolkit for a PE-backed dental roll-up. This breadth of methodology is part of what makes healthcare intellectually demanding and why interviewers test for it aggressively.
Non-Cyclical Demand and Demographic Tailwinds
Healthcare is one of the few sectors where deal activity remains robust through economic downturns. People need cancer treatment, surgical procedures, and prescription medications regardless of GDP growth. The US population over 65 is growing by roughly 2 million per year, creating a structural demand tailwind for virtually every healthcare category.
This recession resistance has practical implications for your career. Healthcare IB groups are less likely to face severe headcount reductions during downturns compared to groups tied to cyclical industries. Deal flow may shift (fewer large pharma M&A transactions during market dislocations, more restructuring activity), but the overall volume of healthcare transactions remains more stable than in sectors like industrials, real estate, or energy.
The Career Specialization Tradeoff
The depth of domain knowledge required in healthcare creates a natural career specialization. After two to three years in healthcare IB, you will have developed expertise in regulatory frameworks, clinical development, reimbursement economics, and sub-sector-specific valuation methods that do not transfer directly to other coverage groups. This specialization is a double-edged sword.
On the positive side, it creates a career moat. Healthcare PE firms, biotech hedge funds, pharma corporate development teams, and life science VCs specifically seek professionals with healthcare banking backgrounds. The exit opportunities are exceptional in both quality and variety. On the other hand, pivoting to a non-healthcare buyside role is harder than it would be from a generalist group. For most candidates, this tradeoff is overwhelmingly positive, but it is worth acknowledging that choosing healthcare IB is choosing a sector for the long term.
Free Interview PDF Guide